Results 11 to 20 of about 213,913 (289)

IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM

Journal for ImmunoTherapy of Cancer, 2023
Introduction The immunosuppressive tumor microenvironment (TME) is a major barrier to the efficacy of chimeric antigen receptor T cells (CAR-T cells) in glioblastoma (GBM).
M. Zannikou, J. Duffy, R. Levine, M. Seblani, Qianli Liu, Aaron Presser, V. Arrieta, Christopher J Chen, A. Sonabend, C. Horbinski, Catalina Lee-Chang, J. Miska, M. Lesniak, S. Gottschalk, Irina V. Balyasnikova   +14 more
semanticscholar   +1 more source

Immune Checkpoint Inhibition in GBM Primed with Radiation by Engineered Extracellular Vesicles.

ACS Nano, 2022
The lack of safe and effective delivery across the blood-brain barrier and the profound immune suppressive microenvironment are two main hurdles to glioblastoma (GBM) therapies. Extracellular vesicles (EVs) have been used as therapeutic delivery vehicles
Tian Tian, Ruyu Liang, Gülşah Erel-Akbaba, Lorenzo Saad, P. Obeid, Jun Gao, E. Chiocca, R. Weissleder, B. Tannous   +8 more
semanticscholar   +1 more source

Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma

OncoImmunology, 2021
T cell-engaging therapies involving bispecific T cell engager (BiTE) and chimeric antigen receptor T (CAR-T) cells have achieved great success in the treatment of hematological tumors.
Gaowei Li, Zongliang Zhang, Linjun Cai, Xin Tang, Jianhan Huang, Lingyu Yu, Guoqing Wang, Kunhong Zhong, Yi Cao, Chang Liu, Yuelong Wang, Aiping Tong, Liangxue Zhou   +12 more
doaj   +1 more source

Advances in nanotechnology for the treatment of GBM

Frontiers in Neuroscience, 2023
Glioblastoma (GBM), a highly malignant glioma of the central nervous system, is the most dread and common brain tumor with a high rate of therapeutic resistance and recurrence.
Dongyan Wei, Nianzu Zhang, S. Qu, Hao Wang, Jin Li   +4 more
semanticscholar   +1 more source

Typification of names published by Schultz “Bipontinus” in the Andryala pinnatifida complex (Cichorieae, Asteraceae), from the Canary Islands

Anales del Jardín Botánico de Madrid, 2020
Schultz “Bipontinus” (1805-1867) described, in the Histoire Naturelle des Îles Canaries published by Webb and Berthelot in 1849, several forms of the Andryala pinnatifida complex, endemic to the Canary Islands, based on plant material collected by E ...
Maria Zita Ferreira, Inés Álvarez Fernández, Miguel Menezes de Sequeira   +2 more
doaj   +1 more source

An Ordinary Short Gamma-Ray Burst with Extraordinary Implications: Fermi-GBM Detection of GRB 170817A [PDF]

, 2017
On 2017 August 17 at 12:41:06 UTC the Fermi Gamma-ray Burst Monitor (GBM) detected and triggered on the short gamma-ray burst (GRB) 170817A. Approximately 1.7 s prior to this GRB, the Laser Interferometer Gravitational-wave Observatory triggered on a ...
A. Goldstein, P. Veres, E. Burns, M. Briggs, R. Hamburg, D. Kocevski, C. Wilson-Hodge, R. Preece, S. Poolakkil, O. Roberts, C. Hui, V. Connaughton, J. Racusin, A. Kienlin, T. D. Canton, N. Christensen, N. Christensen, T. Littenberg, K. Siellez, L. Blackburn, J. Broida, E. Bissaldi, E. Bissaldi, W. Cleveland, M. Gibby, M. Giles, R. Kippen, S. McBreen, J. Mcenery, C. Meegan, W. Paciesas, M. Stanbro   +31 more
semanticscholar   +1 more source

Targeting the splicing factor NONO inhibits GBM progression through GPX1 intron retention

Theranostics, 2022
Background: Splicing factors are essential for nascent pre-mRNA processing and critical in cancer progression, suggesting that proteins with splicing functions represent potential molecular targets for cancer therapy.
Xu Wang, Mingzhi Han, Shuai Wang, Yanfei Sun, Wenbo Zhao, Z. Xue, Xian-Cai Liang, Bin Huang, Gang Li, Anjing Chen, Xing-Yong Li, Jian Wang   +11 more
semanticscholar   +1 more source

Biomimetic GBM-targeted drug delivery system boosting ferroptosis for immunotherapy of orthotopic drug-resistant GBM

Journal of Nanobiotechnology, 2022
Clinical studies have shown that the efficacy of programmed cell death receptor-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors on glioblastoma (GBM) is much lower than what is expected because of the low immunogenicity of GBM.
Bao Liu, Qi-feng Ji, Ying Cheng, Miao Liu, Bangle Zhang, Q. Mei, Dao-zhou Liu, Si-yuan Zhou   +7 more
semanticscholar   +1 more source

Salinomycin-Loaded Iron Oxide Nanoparticles for Glioblastoma Therapy

Nanomaterials, 2020
Salinomycin is an antibiotic introduced recently as a new and effective anticancer drug. In this study, magnetic iron oxide nanoparticles (IONPs) were utilized as a drug carrier for salinomycin for potential use in glioblastoma (GBM) chemotherapy.
Mohammad Norouzi, Vinith Yathindranath, James A. Thliveris, Donald. W Miller   +3 more
doaj   +1 more source

COX4-1 promotes mitochondrial supercomplex assembly and limits reactive oxide species production in radioresistant GBM

Cell Stress, 2022
Glioblastoma (GBM) is a fatal disease with recurrences often associated with radioresistance. Although often effective at treating newly diagnosed GBM, increasing evidence suggests that radiotherapy-induced alterations in tumor metabolism promote GBM ...
Claudia R. Oliva, Md Yousuf Ali, Susanne Flor, Corinne E. Griguer   +3 more
doaj   +1 more source